Nrf2 serves as a key regulator in chemotherapeutic resistance under hypoxia through ROS-Nrf2-GCLC-GSH pathway, and can be a potential treatment for hypoxia-induced drug resistance in breast cancer cells. The gene discussed is GCLC; the disease is breast carcinoma.